SCHEMBL31359074

SCHEMBL31359074

C[C@H](NC(=O)Cn1c(=O)[nH]c2cccc(F)c2c1=O)c1ncc(C#N)cc1F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GPR139 Q6DWJ6 7/20 0.39
▸ FEN1 P39748 1/20 0.38
▸ JAK2 O60674 2/20 0.36
▸ JAK3 P52333 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ITGB1 P05556 1/20 0.35
▸ ITGAV P06756 1/20 0.35
▸ ITGA5 P08648 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ S1PR3 Q99500 1/20 0.34
▸ GRIN1 Q05586 4/20 0.33
▸ GRIN2B Q13224 4/20 0.33
▸ ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359020 1.00 GPR139 (0.39) GPR139FEN1JAK2JAK3KDM4E
SCHEMBL31359077 0.93 ELANE (0.37) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31358993 0.93 ELANE (0.37) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31161003 0.91 PDPK1 (0.36) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31359142 0.91 KDM4E (0.37) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31359019 0.91 PDPK1 (0.36) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31359025 0.91 KDM4E (0.37) GPR139JAK2JAK3KDM4EALDH1A1
SCHEMBL31359011 0.90 GPR139 (0.35) GPR139KDM4EALDH1A1HPGDTSHR
SCHEMBL31358984 0.90 GPR139 (0.35) GPR139KDM4EALDH1A1HPGDTSHR
SCHEMBL31359030 0.89 ITGB1 (0.36) GPR139JAK2JAK3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 GPR139 4045/4885FEN1 3928/4885JAK2 967/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 GPR139 3566/4885FEN1 3297/4885JAK2 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback